BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

961 related articles for article (PubMed ID: 10804042)

  • 21. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
    Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
    Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesalazine for the treatment of inflammatory bowel disease.
    Criscuoli V; Modesto I; Orlando A; Cottone M
    Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis.
    McCormack PL; Robinson DM; Perry CM
    Drugs; 2007; 67(17):2635-42. PubMed ID: 18034594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease.
    Suzuki Y; Iida M; Ito H; Tachikawa N; Hibi T
    Drugs R D; 2016 Mar; 16(1):35-43. PubMed ID: 26883035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J; Yuan Y
    Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review article: aminosalicylates in inflammatory bowel disease.
    Hanauer SB
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
    Gibson PR; Fixa B; Pekárková B; Bátovský M; Radford-Smith G; Tibitanzl J; Gabalec L; Florin TH; Greinwald R
    Aliment Pharmacol Ther; 2006 Apr; 23(7):1017-26. PubMed ID: 16573804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study.
    Paoluzi OA; Iacopini F; Pica R; Crispino P; Marcheggiano A; Consolazio A; Rivera M; Paoluzi P
    Aliment Pharmacol Ther; 2005 May; 21(9):1111-9. PubMed ID: 15854173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB; Goa KL
    Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
    Timmer A; McDonald JW; Tsoulis DJ; Macdonald JK
    Cochrane Database Syst Rev; 2012 Sep; (9):CD000478. PubMed ID: 22972046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.
    Nishikawa AM; Paladini L; Delfini R; Kotze PG; Clark O
    Arq Gastroenterol; 2013; 50(4):297-303. PubMed ID: 24474233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
    Timmer A; Patton PH; Chande N; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD000478. PubMed ID: 27192092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.
    Marteau P; Crand J; Foucault M; Rambaud JC
    Gut; 1998 Feb; 42(2):195-9. PubMed ID: 9536943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.